立方制药（003020）：集采出清，哌甲酯三层芯片获批，业绩有望迎来反转

Investment Rating - The report upgrades the investment rating of the company to "Buy-B" [4][9] Core Views - The company is expected to see a turnaround in performance due to the clearance of centralized procurement risks and the approval of the methylphenidate three-layer chip, which is anticipated to significantly boost revenue [4][9] - The company reported a revenue of 1.518 billion yuan in 2024, a year-on-year decline of 20.11%, but showed signs of recovery with a 7.98% year-on-year increase in Q1 2025 revenue [4][11] - The gross margin improved to 69.16%, up 17.68 percentage points year-on-year, indicating better cost management and product pricing strategies [4][11] Financial Performance Summary - In 2024, the company achieved a net profit of 161 million yuan, down 29.15% year-on-year, but Q1 2025 net profit increased by 25.94% year-on-year to 38 million yuan [4][11] - The projected revenues for 2025, 2026, and 2027 are 1.919 billion yuan, 2.404 billion yuan, and 2.988 billion yuan respectively, with corresponding net profits of 212 million yuan, 281 million yuan, and 370 million yuan [9][11] - The earnings per share (EPS) are expected to be 1.11 yuan, 1.47 yuan, and 1.94 yuan for the years 2025, 2026, and 2027 respectively, with price-to-earnings (P/E) ratios of 21.7, 16.4, and 12.4 [9][11] Market Position and Product Development - The company has successfully launched several products, including the methylphenidate sustained-release tablets, which are expected to capture a significant market share due to the high prevalence of ADHD among children and adolescents in China [7][8] - The company has established a strong position in the market for controlled-release formulations, leveraging its proprietary technology and a diverse product portfolio [7][8] - The marketing strategy has been optimized to ensure sustainable growth, focusing on enhancing terminal management and improving channel management [8]